A claudin5-binding peptide enhances the permeability of the blood-brain-barrier

Berselli, A.; Trevisani, M.; Alberini, G.; Centonze, E.; Vercellino, S.; Cartocci, V.; Millo, E.; Ciubanu, D. Z.; Armirotti, A.; Pisani, F.; Zara, F.; Castagnola, V.; Maragliano, L.; Benfenati, F.

doi:10.1101/2024.04.29.591687

bioRxiv · 10.1101/2024.04.29.591687

A claudin5-binding peptide enhances the permeability of the blood-brain-barrier

Berselli, A.·Trevisani, M.·Alberini, G.·Centonze, E.·Vercellino, S.·Cartocci, V.·Millo, E.·Ciubanu, D. Z.·Armirotti, A.·Pisani, F.·Zara, F.·Castagnola, V.·Maragliano, L.·Benfenati, F.

View original source ↗Export metadata ↓

Abstract

The blood-brain barrier (BBB) is essential to maintain brain homeostasis and healthy conditions but it also prevents drugs from reaching brain cells. In the BBB, tight junctions (TJs) are multi-protein complexes located at the interface between adjacent brain endothelial cells that regulate paracellular diffusion and claudin-5 (CLDN5) is the major component of the TJ portfolio, playing a pivotal role in restricting the paracellular traffic. In view of obtaining fine control over the transport across the BBB, the use of competing peptides able to bind CLDN5 to induce transient and regulated permeabilization of the paracellular passage is emerging as a potentially translatable strategy for clinical applications. In this work, we designed and tested short peptides with improved solubility and biocompatibility using a combined approach that involved structural modeling techniques and in vitro validation, generating a robust workflow for the design, screening, and optimization of peptides for the modulation of the BBB paracellular permeability. We designed a selection of 11- to 16-mer compounds derived from the first CLDN5 extracellular domain and from the CLDN5-binding domain of Clostridium perfringens enterotoxin and determined their efficiency in enhancing BBB permeability. The computational analysis classified all tested peptides based on solubility and affinity to CLDN5, and provided atom-level details of the binding process. From our screening, we identified a novel CLDN5-derived peptide, here called f1-C5C2, which demonstrated good solubility in biological media, efficient binding to CLDN5 subunits, and capability to increase permeability at low concentrations. The peptidomimetic in silico/in vitro strategy described here can achieve a transient and reversible permeabilization of the BBB with potential applications in the pharmacological treatment of brain diseases. HIGHLIGHTSO_LIWater-soluble peptidomimetics are used to competitively bind claudin-5 tight junction proteins and increase the permeability of the blood-brain barrier; C_LIO_LITrans-endothelial electrical resistance and dissociation constant measurements demonstrate the binding affinity of the peptide f1-C5C2 for claudin-5; C_LIO_LIUnbinding free energy calculations correlated with experimental results and provided information on the protein-peptide binding interface. C_LIO_LIIncubation with the peptide f1-C5C2 allows paracellular transport of 4K, but not 70K, dextran. C_LI GRAPHICAL ABSTRACT O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=88 SRC="FIGDIR/small/591687v1_ufig1.gif" ALT="Figure 1"> View larger version (30K): org.highwire.dtl.DTLVardef@70fe54org.highwire.dtl.DTLVardef@496a28org.highwire.dtl.DTLVardef@1d89a81org.highwire.dtl.DTLVardef@187acec_HPS_FORMAT_FIGEXP M_FIG C_FIG

Source connections

Published article ↗

Explore related subjects

neuroscience Preprint

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

Berselli, A., Trevisani, M., Alberini, G., Centonze, E., Vercellino, S., Cartocci, V., Millo, E., Ciubanu, D. Z., Armirotti, A., Pisani, F., Zara, F., Castagnola, V., Maragliano, L., Benfenati, F.. 2024-04-30. A claudin5-binding peptide enhances the permeability of the blood-brain-barrier. https://doi.org/10.1101/2024.04.29.591687

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

CoReg, tracking-based motion compensation for in vivo calcium imaging

In vivo calcium imaging enables the observation of neural activity with high spatial and temporal resolution. However, recordings are frequently affected by motion artifacts caused by animal movement, physiological processes, tissue drift, or instability of the imaging setup. These artifacts make signal extraction harder and reduce the consistency of downstream analyses. Current registration methods can correct rigid and non-rigid motion, but often estimate motion from individual frames or image patches and make limited use of temporal information. In addition, activity-driven fluorescence changes can make it difficult to distinguish changes in image appearance from actual motion. Here, we treat motion correction in calcium imaging as a point tracking problem and introduce CoReg, an open-source Python- based software tool with a graphical user interface. We benchmark CoReg against established registration methods using fluorescence imaging datasets from multiple species. CoReg performs competitively with or better than existing approaches across several settings. We further show that its performance is robust to the choice of tracked points, making the method straightforward to apply. CoReg includes implementations of both our method and the evaluated established methods. Our results show that tracking-based registration provides a simple and reliable approach for motion correction in vivo calcium imaging.

neuroscience↗

bioRxiv2026

A shared slowing axis and phenotype-specific rhythms link clinical EEG to FDG-PET dementia phenotypes

Early and accurate identification of neurodegenerative disorders has notable implications for treatment and quality of life. Whereas neuroimaging-based biomarkers can accurately identify neurodegenerative subtypes, EEG represents a low-cost alternative that could expand access to dementia care. Here, we investigated whether six data-driven EEG latent factors, derived by nonnegative tensor decomposition of clinical EEGs, differ systematically across FDG-PET-defined neurodegenerative phenotypes. In 455 patients with EEG and FDG-PET acquired within one year of each other, factor expression was compared across 14 diagnostic classes assigned by StateViewer, a validated artificial intelligence framework for FDG-PET interpretation. To separate disease-general severity from phenotype-specific topography, each factor was also regressed on a subject-level slowing index. Finally, we related the factors to regional FDG uptake and to neuropsychological performance (n = 98) and assessed their potential utility for single-subject classification. Four factors reflecting neurophysiological oscillations (posterior alpha, Rolandic beta, frontotemporal delta-theta and posterior theta-slow alpha) varied significantly across phenotypes, with attenuation of faster and augmentation of slower rhythms most pronounced in dementia with Lewy bodies (DLB), dysexecutive Alzheimer disease (AD) and posterior cortical atrophy, whereas factors dominated by eye-movement and muscle artifact showed no robust phenotypic association. Alpha and beta effects were largely attributable to overall slowing, whereas posterior theta-slow alpha became more phenotype-specific after adjustment (eta-squared 0.082 to 0.147), dissociating the Alzheimer disease spectrum from frontotemporal syndromes. The slowing index tracked with an FDG-PET pattern highly associated with DLB across the cohort, irrespective of assigned phenotype (r = 0.51, P < 0.001). Consistent with a model in which dementia phenotypes reflect altered hippocampal-neocortical oscillatory coupling (stochastic latent oscillatory diffusion), frontotemporal delta-theta tracked a limbocortical axis of metabolic pattern expression, rising with neocortical and falling with limbic-predominant involvement, independent of overall slowing and phenotype. Each factor mapped onto a distinct metabolic topography, with frontotemporal delta-theta resembling Alzheimer-type hypometabolism and posterior theta-slow alpha the medial occipital hypometabolism of DLB. In terms of neuropsychological performance, Rolandic beta was associated with executive functions, and frontotemporal delta-theta with memory, visuospatial and global performance. Using these four factors alone, an exploratory logistic regression classifier separated cognitively unimpaired participants from DLB, posterior cortical atrophy, typical AD, and dysexecutive AD (area under the curve > 0.8) but poorly discriminated frontotemporal dementia phenotypes canonically associated with 4-repeat tau. Thus, data-driven decomposition of clinical EEG separates oscillatory activity from artifact into factors that track metabolic phenotype, regional metabolism and cognition, capturing both overall slowing and phenotype-specific patterns. This work informs the further development of scalable, biology-informed EEG-based phenotyping of neurodegenerative disease.

neuroscience↗

bioRxiv2026

An application of fNIRS for the prediction of hearing thresholds in sleeping infants: a proof of principle

This study applied a two-component-response modelling approach to fNIRS recordings obtained from naturally sleeping infants presented with auditory stimuli at different sound intensities. We investigated whether the relationship between fNIRS response measures and stimulus intensity could be modelled to estimate individual auditory hearing thresholds. In the normal-hearing group, 75% of infants had threshold estimates for the sound /ba/ within the expected normal-hearing range, with an estimated mean equivalent normal loudness (ENL) of 10.72 dB HL (SD 8.64 dB HL). A case study further explored the potential application of this approach in an infant with hearing impairment, highlighting the importance of reliable responses at lower stimulus intensities and appropriate regression model selection. These findings provide preliminary evidence that cortical haemodynamic responses can be quantitatively related to sound intensity for estimating auditory sensitivity.

neuroscience↗